Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-005234
Filing Date
2017-07-21
Accepted
2017-07-21 10:47:43
Documents
42
Period of Report
2017-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nvls-20170630x10q.htm 10-Q 1092775
2 EX-31.1 nvls-20170630ex311e6f0d9.htm EX-31.1 19650
3 EX-32.1 nvls-20170630ex3211e4d51.htm EX-32.1 7235
  Complete submission text file 0001558370-17-005234.txt   3322068

Data Files

Seq Description Document Type Size
4 EX-101.INS nvls-20170630.xml EX-101.INS 601064
5 EX-101.SCH nvls-20170630.xsd EX-101.SCH 20959
6 EX-101.CAL nvls-20170630_cal.xml EX-101.CAL 26712
7 EX-101.DEF nvls-20170630_def.xml EX-101.DEF 74457
8 EX-101.LAB nvls-20170630_lab.xml EX-101.LAB 219808
9 EX-101.PRE nvls-20170630_pre.xml EX-101.PRE 153059
Mailing Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301
Business Address 3122 STERLING CIRCLE, SUITE 200 BOULDER CO 80301 720-945-7700
Nivalis Therapeutics, Inc. (Filer) CIK: 0001626199 (see all company filings)

EIN.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37449 | Film No.: 17975741
SIC: 2834 Pharmaceutical Preparations